Skip to main content
BSX
NYSE Industrial Applications And Services

Boston Scientific Reports Strong Q1 Results, Meets EPS Guidance, and Updates Full-Year Outlook

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$58
Mkt Cap
$88.457B
52W Low
$59.385
52W High
$109.5
52W Position info
2.3% below low
Off High info
47% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

BSX is trading near its 52-week low of $59.385 (2.3% below the low).

Summary

Boston Scientific reported Q1 results that met the high end of adjusted EPS guidance, provided updated full-year and new Q2 outlooks, and announced several positive product development and M&A updates.


Key Events · Earnings and Guidance · BSX

  • Strong Q1 Financial Performance

    Reported net sales of $5.203 billion, an 11.6% increase, and adjusted EPS of $0.80, which met the high end of the company's guidance range of $0.78 to $0.80 per share.

  • Updated Full-Year and Q2 Guidance

    Revised full-year 2026 net sales growth to 7.0-8.5% (reported) and adjusted EPS to $3.34-$3.41. For Q2 2026, the company projects net sales growth of 5.5-7.5% (reported) and adjusted EPS of $0.82-$0.84.

  • Positive Clinical Trial Results

    Announced favorable outcomes from the CHAMPION-AF, HI-PEITHO, and ADVENT Long-Term Outcomes clinical trials for key devices like WATCHMAN FLX, EKOS, and FARAPULSE.

  • Regulatory Approvals and Acquisition

    Received NMPA approval in China for the OPAL HDx™ Mapping System and U.S. FDA 510(k) clearance for the Asurys™ Fluid Management System. The acquisition of Valencia Technologies Corporation was also completed.


Analysis · BSX · Industrial Applications And Services

Boston Scientific delivered a strong first quarter, meeting the high end of its adjusted EPS guidance and achieving robust sales growth. The company also provided updated full-year and new second-quarter guidance, which aligns with market expectations. Beyond financials, the filing highlights significant progress in its product pipeline with multiple positive clinical trial results and regulatory approvals, alongside a completed acquisition. These operational achievements, coupled with new board appointments, demonstrate solid execution and strategic advancement, which could be particularly impactful as the stock trades near its 52-week low.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BSX was trading at $58.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $88.5B. The 52-week trading range was $59.39 to $109.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BSX - Latest Insights

BSX
Nov 20, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $41.98
Real-time Price: $42.20 info
Change: +$0.220 (+0.52%) info
Market Cap: $60.878B info
BSX
Nov 19, 2026, 5:16 PM EST
Filing Type: FWP
Importance Score:
7
Price at Filing: $43.07
Real-time Price: $42.20 info
Change: -$0.870 (-2%) info
Market Cap: $60.878B info
BSX
Nov 19, 2026, 4:51 PM EST
Filing Type: FWP
Importance Score:
7
Price at Filing: $43.00
Real-time Price: $42.20 info
Change: -$0.800 (-2%) info
Market Cap: $60.878B info
BSX
Nov 19, 2026, 8:38 AM EST
Filing Type: 424B5
Importance Score:
7
Price at Filing: $43.36
Real-time Price: $42.20 info
Change: -$1.16 (-3%) info
Market Cap: $60.878B info
BSX
Nov 19, 2026, 6:03 AM EST
Filing Type: 424B5
Importance Score:
7
Price at Filing: $43.51
Real-time Price: $42.20 info
Change: -$1.31 (-3%) info
Market Cap: $60.878B info